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Abstract
Metabolomics is the study of metabolome within cells, biofluids, tissues, or
organisms to comprehensively identify and quantify all endogenous and exogenous
low-molecular-weight (<1 kDa) small molecules/metabolites in a biological system
in a high-throughput manner. Metabolomics has several applications in health and
disease including precision/personalized medicine, single cell, epidemiologic popu-
lation studies, metabolic phenotyping, and metabolome-wide association studies
(MWAS), precision metabolomics, and in combination with other omics disciplines
as integrative omics, biotechnology, and bioengineering. Mass spectrometry (MS)-
based metabolomics/lipidomics provides a useful approach for both identification
of disease-related metabolites in biofluids or tissue and also encompasses classifica-
tion and/or characterization of disease or treatment-associated molecular patterns
generated from metabolites. Here, in this review, we provide a brief overview of
the current status of promising MS-based metabolomics strategies and their
emerging roles, as well as possible challenges.
Keywords: metabolomics, untargeted metabolomics, targeted metabolomics,
omics, mass spectrometry
1. Introduction
Metabolomics is an evolving field to comprehensively identify and quantify all
endogenous and exogenous low-molecular-weight (<1 kDa) small molecules/
metabolites in a biological system in a high-throughput manner. The composition of
these endogenous compounds is affected by the upstream influence of the proteome
and genome as well as environmental factors, lifestyle factors, medication, and
underlying disease. Metabolomics is reported as the reflection of the phenotype.
The metabolome is downstream of the transcriptome and proteome and is consid-
ered to be complementary to genomics, transcriptomics, and proteomics. It has
been reported that due to the close relation of metabolome to the genotype, physi-
ology, and environment of an organism, genotype-phenotype as well as genotype-
envirotype relationships could be successfully documented by metabolomics [1–3].
Metabolomics is the study of metabolome within cells, biofluids, tissues, or
organisms and applied in molecular and personalized medicine involved in clinical
chemistry, transplant monitoring, newborn screening, pharmacology, and toxicol-
ogy. Metabolome can be defined as the small molecules and their interactions
within a biological system which has been estimated as 3000–20,000 global metab-
olite profiles under a given genetic, nutritional, environmental conditions. Since the
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metabolome is the final downstream product, changes and interactions between
gene expression, protein expression, and the environment are directly reflected in
metabolome making it more physically and chemically complex than the other
“omes.” The metabolome is closest to the phenotype among other omics
approaches, and metabolomics best modulates and represents the molecular phe-
notype of health and disease [4]. It has been demonstrated that relations of
genotype-genomics and phenotype-metabolomics refer to specific gene variations
and resultant metabolite changes which ultimately give information about genetic
epigenetic phenotypic changes [1, 5–8]. In this regard, metabolomics is a brilliant
source for biomarker discovery with advantages over other omics approaches.
An overview of first metabolomics experiments has demonstrated metabolite
quantitation in biofluids which was first utilized in 1971 [9, 10]. After that, in the
same year, the first use of the definition of “metabolic profiling” was observed
[9, 11], while “metabolome” was first used in 1998 [9, 12]. In 1999, the term
“metabonomics” was described as the quantitative measurement of the dynamic
multiparametric metabolic response of living systems to pathophysiological stimuli
or genetic modification [13].
Due to the complexity of the metabolome, a wide variety of chemically diverse
compounds such as lipids, organic acids, carbohydrates, amino acids, nucleotides,
and steroids, among others, have not yet been validated and reported totally; thus,
we do not know the complete number of metabolites present in the human [14].
Human Metabolome Database (HMDB; http://www.hmdb.ca, version 4.0, 2018)
reported 114,098 (April 2019) metabolite entries including both water-soluble and
lipid-soluble metabolites as well as metabolites that would be regarded as either
abundant (>1 uM) or relatively rare (<1 nM). Those small molecules, which have
been identified and experimentally confirmed in various human tissues and
biofluids, have been suggested as only 20% of the total metabolome [15]. Addition-
ally, 5702 protein sequences are linked to these metabolite entries. The database also
contained listing normal and abnormal concentrations of different metabolites for
23 different biospecimens.
Metabolomics strategies cover two primary analysis platforms including
“untargeted-discovery-global” and “targeted-validation-tandem” based on the
objective of the study (Figure 1). In order to systematically identify and quantify
metabolites from a biological sample and achieve comprehensive characterization
of biomarker targets, the analysis considers both endometabolome and
exometabolome. Untargeted discovery metabolomics has a hypothesis-generating
manner and allows for full scanning of the metabolome, pattern identification, and
“metabolic fingerprinting” for the global classification of phenotypes with
interacting pathway interactions. Targeted metabolomics is hypothesis testing and
generally performed for validation of an untargeted analysis. In the targeted
approaches (tandem-MS/MS), using a known standard, a quantitative analysis is
performed on specific small molecules/metabolites or perturbations along a meta-
bolic pathway [9] also known as “biased or directed metabolomics” or “metabolic
profiling.” Hypothesis-generating metabolomics covers different strategies as
(i) nontargeted profiling, (ii) fingerprinting, and (iii) footprinting [16], while
hypothesis-testing strategies are target analysis and diagnostic analysis.
Nontargeted global metabolomics profiling refers to comprehensive metabolite/
small molecule analysis. This analysis performs semiquantitative analysis with
putative identifications of the detected features. Metabolomics fingerprint exam-
ines global snapshot of the intracellular metabolome enabling classification and
screening, while metabolomics footprint analysis explores global snapshot of the
extracellular fluid metabolome (secretions from cells or changes in metabolites
consumed from the exometabolome). Quantification and identification of the
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features do not comply with fingerprint and footprint metabolomics. Metabolomics
strategies for validation purposes refer to quantitative tandem/targeted analysis
and diagnostic analysis of a known clinical associated compound/biomarker [16].
Untargeted and targeted approaches should be performed consecutively in order to
achieve an accurate identification and absolute quantitation of the metabolites [9].
Here, in this review, we provide a brief overview of the current status of promising
MS-based metabolomics strategies and their emerging roles, as well as possible
challenges.
2. Basic workflow of MS-based metabolomics
MS is used to identify and quantify metabolites even at very low concentrations
(femtomolar to attomolar) with high resolution, sensitivity, and dynamic range
[17]. MS-based analyses basically include sample preparation, extraction, capillary
electrophoresis (CE), and/or chromatographic separation, introduction of sample
for ionization process (charged molecules), and detection of possible metabolites on
the basis of their mass-to-charge ratio (m/z). In this review, the main aspects of
MS-based untargeted metabolomics strategies are briefly outlined below:
1.Sample acquisition:Metabolome analysis can be performed in various
biological samples including tissue, biofluids (blood, urine, feces, seminal
fluid, saliva, bile, cerebrospinal fluid), and cell culture [18] (Table 1). Careful
sampling, sample preparation and management, and sample biobanking/
biorepositories together with sample labeling are critical and essential for an
Figure 1.
Metabolomics workflow with main bulleted points.
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Types of biospecimen Sample acquisition and preparation
Tissue • Mechanical and nonmechanical homogenization
can be performed for tissues, cells, and other
biological samples
• Mechanical homogenization include
homogenizer, ultrasound, microwave, manual
grinding, ball mill, and grinding in a liquid
nitrogen-cooled mortar and pestle
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
Suspension-
cultured
mammalian cells
Cells (intracellular-
fingerprint-metabolite
profiling)
• Quenching with ice-cold 50 mM ammonium
bicarbonate + methanol
• Centrifuge at 1000g for 1 min at 20°C
• Removal of the media/quenching solution from
the cells
• Snap freeze in liquid nitrogen
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
Cell medium (extracellular-
footprint-metabolite
profiling)
• Centrifuge the media at 500g for 5 min (remove
cells)
• Remove supernatant
• Snap freeze in liquid nitrogen
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
Biofluids Serum • Blood samples should be collected into serum
separator tubes and incubate 30 min and no
longer than 60 min for clotting procedure on ice
instead of room temperature to minimize residual
metabolic activity
• At the end of the clotting time, the blood sample is
centrifuged or 20 min at 1100–1300g at ambient
temperature
• The serum visible in the upper layer of the tube as
supernatant is collected and stored at 80°C, and
freeze-thaw cycles are avoided
Plasma • Blood samples collected into heparin, citrate,
or EDTA-containing tubes under fasting
conditions
• Centrifuge at 13,000g, 15 min, 4°C
• Supernatant isolation and removal
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
• Various coagulants such as heparin, citrate, or
EDTA represent different retention time peaks
Cerebrospinal fluid (CSF) • CSF sampling via lumbar puncture
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
• To obtain highly resolved chromatograms, careful
handling is essential in case of blood-
contaminated CSF sample
Urine • Sodium azide addition to the sample as
bacteriostatic agent during sample storage
• 0.2 μm filtration for each sample in order to avoid
any particulates
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optimum, reproducible, and high-throughput analysis with high recovery,
extraction, and enriched metabolite coverage.
2.Sample preparation/extraction: During sample preparation different
extraction solvents/methods are used for high recovery of both polar and
nonpolar compounds based on nontargeted and targeted approaches on
Types of biospecimen Sample acquisition and preparation
• Centrifuge at 1000–3000 rcf for 5 min
• Removing supernatant
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
Saliva • 3 mL saliva samples collected into sample tubes
under fasting conditions
• Aliquoting
• Storage at 80°C
Sweat • Sweat secretion is stimulated by exercise, heat, or
chemicals such as pilocarpine
• The skin area is cleaned with ethanol and then
with distilled water
• The sweat is collected by using a micropipette
(from 20 to 200 μL at least 100 μL)
• The minimum sweat rate demanded to obtain a
valid sweat sampling is 1 g/m2 per min
• The use of deodorants, perfumes, and cosmetics
was excluded at least 1 day prior to sweat
collection
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
Feces • A single spot 1–2 g of feces
• Storage at 80°C
Breath • Exhaled breath condensate (EBC) upon 8 h of
fasting including smoking is performed
• Collecting time for EBC is 20 min, producing
approximately 1 mL condensate sample
• Commercial collection samplers, bags, and
devices are used
• Compatible with GC, GC-MS
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
Seminal plasma • Semen is centrifuged at 700g, 4°C, 10 min
• Supernatant (seminal plasma) is separated
• Supernatant seminal plasma is recentrifuged at
10,000g, 60 min, 4°C
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
Bile • 2 mL gallbladder bile is collected intraoperatively
• Aliquoting
• Storage at 80°C
• Freeze-thaw cycles avoided
Table 1.
Systematic collection and storage of human samples for metabolomics/lipidomics strategies.
5
Metabolomics: Basic Principles and Strategies
DOI: http://dx.doi.org/10.5772/intechopen.88563
different biological samples involving tissue, blood, plasma, serum, cells,
urine, etc. Basically applied approaches include optimized methanol-water-
chloroform combinations to extract both hydrophilic and hydrophobic
compounds. For high recovery of both hydrophilic and hydrophobic
compounds, separate extraction applications give better results. During sample
preparation after the centrifugation process, a biphasic mixture of the upper
(aqueous) and lower (organic) layers is extracted separately. In the two
sequential or two-phase extraction applications optimized for both polar and
nonpolar metabolites such as lipids, an aqueous extraction using polar organic
solvents (e.g., methanol or acetonitrile) mixed with water followed by
organic extraction (lipid extraction) with dichloromethane or chloroform-
methanol is carried out [16, 19]. The first one of the two-phase extractions
involves aqueous solvent (e.g., methanol-water) followed by extraction with a
nonpolar solvent (e.g., chloroform) of the centrifuged pellet.
3.Separation: Chromatographic separation techniques including liquid
chromatography (LC) and gas chromatography (GC) are used coupling to MS
systems (GC-MS, HPLC-MS, UPLC-MS), while direct injection techniques
include direct infusion MS [20] and direct analysis in real-time MS (DART-
MS) [21, 22]. In addition, capillary electrophoresis (CE) coupled to MS systems
(CE-MS) is an important technique for separation and profiling of polar
metabolites in biological samples. Reversed-phase LC using C18 columns is
used for separation of nonpolar compounds, while hydrophilic interaction
chromatography (HILIC) is used for separation of polar compounds [23].
Gas chromatography/mass spectrometry (GC/MS) is one of the widely used
untargeted and targeted metabolomics platforms which offer high chromatographic
resolution. In addition to other compounds, volatile organic compounds (VOCs)
such as fatty acids and organic acids which are important biomarker candidates in
biological samples can be successfully achieved by GC-MS. Analysis by GC-MS
requires derivatization with reactions of alkylation, acylation, and silylation in order
to increase detection or retention of the compound [24].
Volatile organic compounds are important components of the metabolome and
include metabolites such as alcohols, alkanes, aldehydes, furans, ketones, pyrroles,
and terpenes. Volatilomics is a new field with adductomics into the metabolomics.
For the extraction of VOCs, solvent-free sample preparation/extraction method
“solid-phase microextraction (SPME)” is used, which enables extraction of organic
compounds from gaseous, aqueous, and solid materials [24].
LC/MS and GC-MS have different sensitivities for detecting metabolites with
high recovery/coverage. Compared to GC/MS, a wide range of molecular features
can be analyzed via LC-MS. GC-MS is capable of analyzing less polar biomolecules
involving alkylsilyl derivatives, eicosanoids, essential oils, esters, perfumes,
terpenes, waxes, volatiles, carotenoids, flavonoids, and lipids. LC-MS is capable of
analyzing more polar biomolecules involving organic acids, organic amines,
nucleosides, ionic species, nucleotides, and polyamines and does not require
derivatization. Both LC-MS and GC-MS are able to analyze alcohols, alkaloids,
amino acids, catecholamines, fatty acids, phenolics, polar organics, prostaglandins,
and steroids [25].
4.Ionization: After chromatographic separation, samples are pumped through
MS capillary to obtain positive or negative electrically charged ions in gas
phase. Introduction of heat and dry nitrogen in the MS cause the droplets to
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evaporate. Then the resultant evaporated droplets transfer the charge to the
analytes and ionize them both in the positive and negative mode via charge
transfer [26]. Polarity of the ionization/ion sources has great importance for
avoiding metabolites’ losses. Based on the polarity of the molecule, applied
ionization sources include electron ionization (EI), chemical ionization (CI),
electrospray ionization source (ESI), atmospheric pressure chemical ionization
(APCI), atmospheric pressure photo-ionization (APPI), and matrix assisted
laser desorption ionization (MALDI) [27–31].
5.Detection: High-resolution mass spectrum composed of mass-to-charge (m/z)
ratios of fragment ions created by ionized biomolecules is detected by MS at
sub-femtomole levels. Mass analyzers include time of flight (TOF),
quadrupole time of flight (QTOF), quadrupole, ion trap, and orbitrap. For
targeted metabolomics analysis, tandem or MS/MS is performed for validation
of potentially discovered metabolites during untargeted analysis. For MS/MS,
ion trap or triple quadrupole (QQQ) with multiple reaction monitoring
(MRM) is generally used with high sensitivity, mass resolution, and accuracy
(<1 ppm mass error) [9].
6.Data analysis and metabolite identification: The large amounts of complex
raw data involving specific metabolic signals are extracted from MS and
analyzed in specialized software to properly interpret the data and identify
the metabolite of interest. Commercially available and free software
bioinformatic analysis tools automatically perform processing of peak
selection, assessment, and relative quantitation. Raw data signal spectrum
preprocessing includes background spectral filtering (noise elimination),
retention time correction, appropriate peak assignment for the same
compound (identification of matching m/z and assigning adducts
appropriately), peak detection, peak alignment (matching peaks across
multiple samples) and peak normalization (adjusting peak intensities and
reducing analytical drift), and chromatogram alignment. Following this, data
preparation includes data integrity checking, data normalization, and
compound name identification using the univariate, multivariate, clustering,
and classification statistical analyses [32]. Following data processing, data
interpretation, and metabolite identification from mass spectrum can be
performed with the following: functional interpretation, enrichment analysis,
pathway analysis, and metabolite pathway networks mapping. Commonly
used tools include XCMS [33], Metaboanalyst [34], Progenesis [35], MetaCore
[36], and 3Omics [37], with different analysis capabilities. The software
processes raw mass spectrum data, perform various statistical analyses to find
significantly altered ions/features, and for metabolite identifications connect
to the metabolite database search such as Human Metabolome Database
(HMDB) [14], Metabolite and Tandem MS Database (METLIN) [38], LIPID
MAPS [39], Madison Metabolomics Consortium Database (MMCD) [40],
BiGG [41], SetupX [42], KNApSAcK [43], and MetaboLights [44]. Compound
or compound-specific databases include PubChem [45], Chemical Entities of
Biological Interest (ChEBI) [46], ChemSpider [47], The KEGG GLYCAN [48],
KEGG COMPOUND [49], and In Vivo/In Silico Metabolites Database
(IIMDB) [50]. Metabolic pathway databases include Kyoto Encyclopedia of
Genes and Genomes (KEGG) [51], BiKEGG [52], KEGG PATHWAY [53],
MetaCyc [54], BioCyc [54], Model SEED [55], Reactome [56], and Ingenuity
Pathway Analysis (IPA) [57].
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3. Challenges and affecting factors
Though there are extensive tools and databases for analysis and identification of
metabolites, challenges remain in the field of data analysis/integration, pathway
analysis, and metabolite identification in untargeted metabolomics due to the high-
throughput heterogeneous omics data which essentially requires improved bioin-
formatics and computational techniques to comprehensively evaluate the
metabolomic profiles and completion of the human metabolome [32, 58–62].
Chromatographic resolution, absolute MS signals, and compound identification
can be affected during ionization process due to polarity, ion sources, ion suppres-
sion, flow rates, and MS vacuum, sample preparation strategies, purity and tem-
perature (prechilled) of reagents and solvents, different laboratory staff and
techniques in different analysis days (typical sources of variance), different mass
analyzers, chromatographic separation columns and compositions that cause
forming of different fragments of the same molecule, frequent detection of the
most abundant molecules, ion suppression, and day-day variation. Another chal-
lenge is the existence of isomers with identical masses and highly similar spectra
which complicates distinguishing and differentiation during metabolite assignment
to spectrum features [63, 64].
During the analytical process, a plot of the area internal standard (IS) response
ratio vs. analyte concentration of each sample within a batch is performed to obtain
calibration curves, which are needed to control for accuracy and reproducibility of
the system. Performance monitoring in terms of plots of absolute MS signals,
retention time points, and mass patterns/chromatographic peak shape of the
analytes/ISs are required for maintaining sensitivity, integrity, and robustness of
the analytical results. It has been reported that high system pressure and short
columns with small particle sizes (<2 μm) lead to better signal:noise ratios than
columns with larger particle sizes. Small particle-sized columns also affect the
fastness of screening feature of MS [65–68].
Quality control (QC) sample plots of analytical parameters vs. retention times
and peak shapes during calibration, sample preparation, and the analysis belonging
to each batch as a quality check are essential for optimum standardization. All QC
samples of each batch collected from each sample to create the pooled QC should be
identical to each other and placed 1 in 5–1 in 10 samples in the analyses [16]. During
sample preparation, a general contamination due to matrix compounds occurs and
degrades the analytical system. In order to eradicate those possibilities,
monitorization and randomization using technical QC and pooled QC samples
which involve small aliquots of each biological sample, batch samples, and blanks
considering peak shapes and retention times should be performed. Using a set of
ISs, control samples, and blanks, performance of the method and monitorization
have to be performed. In addition, randomization has to be performed on both
sample preparation and the analysis order of system.
In order to eliminate or minimize methodological challenges, systematic errors,
and bias factor due to analytical drift such as batch effect and obtain analytical
sensitivity and specificity, reproducibility, accurate quantitation, and high recov-
ery + low metabolite losses, each analysis should be carried out specifically under
conditions of method optimization and optimum performance monitoring. Fur-
thermore, using quality control samples and ISs during sample preparation, injec-
tion, extraction, fractionation, separation, detection, and normalization periods is
essential. Generally, stable isotopes are used as the most identical ISs to compounds
of interest in order to obtain accurate identification and to eliminate metabolite
losses and ion suppression.
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4. Metabolomics in health and disease
Metabolomics has several applications in health and disease including precision/
personalized medicine, single cell, epidemiologic population studies, metabolic
phenotyping and metabolome-wide association studies (MWAS), precision
metabolomics, and in combination with other omics disciplines as integrative omics
[69]. Single-cell metabolomics and single-cell lipidomics technologies allow high-
dimensional characterizations of individual cells, disease heterogeneity and com-
plexity, identification, expression and abundance of disease-associated small mole-
cules, metabolites, and by LC-MS/MS, GC-MS/MS, and live single-cell mass
spectrometry (LSCMS) [70]. Imaging MS analysis of human breast cancer samples
at the single-cell level revealed cell-cell interactions and tumor heterogeneity [71].
Clinical biomarkers and different metabotypes of disease severity correlated to
exposures [72], and biological outcomes [73] have been studied and identified
through metabolomics profiling, MWAS, and metabolomics fingerprinting and
footprinting techniques in individuals and populations which will enable precision
medicine and public healthcare [74–79]. Studies moving from genome-wide associ-
ation studies (GWAS) to metabolome-wide association studies (MWAS) were first
described in 2008 as “environmental and genomic influences to investigate the
connections between phenotype variation and disease risk factors” [78–80]. Rattray
and colleagues suggested exposotypes on single individual phenotypes and
populations, in epidemiologic research, and disease risk using metabolome-wide
association studies and impacts on precision medicine [79].
In conclusion, MS-based metabolomics/lipidomics provides a useful approach
for both identification of disease-related metabolites in biofluids or tissue and also
encompasses classification and/or characterization of disease or treatment-
associated molecular patterns generated from metabolites [81, 82].
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